September 18, 2009 - Chugai Pharmaceutical Co., Ltd. announced today that the company filed an application with the Japanese Ministry of Health, Labour and Welfare for the approval of an additional indication of pancreatic cancer for the antineoplastic agent / epidermal growth factor receptor tyrosine kinase inhibitor, "TARCEVA® Tablet 25 mg and 100 mg" [generic name: erlotinib hydrochloride].
The details can be read here.
No comments:
Post a Comment